Helsinki, Finland-based Surgify plans to use the investment to advance its bone surgery technology. The company designs the Halo device for bone cutting in surgical procedures.
According to a news release, conventional surgical drills can bring risks if they come into contact with critical soft tissue. At worst, soft tissue damage can result in severe injury to the patient. Halo cuts bone while providing unique protective capabilities against incidental injuries to soft tissues like central nervous system structures, blood vessels and nerves.
The technology provides effective bone resection in combination with a soft tissue protection feature. It delivers enhanced safety and precision in surgical procedures, Surgify says. Halo has both European and U.S. approval already, according to the company.
Having already brought Halo to the Nordic market, the company plans now to expand operations across Europe and the U.S.
Zeiss Ventures — the venture arm of the Carl Zeiss Group — led the financing round. The European Innovation Council Fund (EIC Fund) also participated with existing investors, including Lednil and Cascara Ventures.
“ZEISS brings unparalleled experience in surgical technology and a global network, while the EIC’s continued support and earlier grant financing underscore the European innovation ecosystem’s confidence in our solution,” said Visa Sippola, co-founder and CEO of Surgify Medical. “With this funding and regulatory approvals in both the EU and the U.S., we are well-positioned to bring our unique technology to more surgeons and patients internationally.”
